V Square Quantitative Management LLC decreased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 25.6% in the second quarter, Holdings Channel.com reports. The institutional investor owned 2,811 shares of the company’s stock after selling 967 shares during the quarter. V Square Quantitative Management LLC’s holdings in Moderna were worth $334,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of MRNA. Quadrant Capital Group LLC grew its holdings in shares of Moderna by 7.5% in the fourth quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company’s stock valued at $266,000 after purchasing an additional 187 shares during the period. abrdn plc grew its holdings in shares of Moderna by 477.5% in the fourth quarter. abrdn plc now owns 483,574 shares of the company’s stock valued at $48,091,000 after purchasing an additional 399,843 shares during the period. Ontario Teachers Pension Plan Board purchased a new stake in shares of Moderna in the fourth quarter valued at about $1,358,000. Hobbs Group Advisors LLC purchased a new stake in shares of Moderna in the fourth quarter valued at about $664,000. Finally, Illinois Municipal Retirement Fund lifted its position in Moderna by 22.1% in the first quarter. Illinois Municipal Retirement Fund now owns 51,791 shares of the company’s stock valued at $5,519,000 after buying an additional 9,360 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.
Moderna Stock Up 4.1 %
Moderna stock traded up $3.34 during mid-day trading on Thursday, hitting $85.59. The company had a trading volume of 332,593 shares, compared to its average volume of 4,099,247. The stock has a market cap of $32.80 billion, a price-to-earnings ratio of -5.25 and a beta of 1.67. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $170.47. The company has a quick ratio of 3.91, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The business has a fifty day moving average of $118.88 and a 200 day moving average of $114.11.
Insider Transactions at Moderna
In other news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $117.08, for a total transaction of $1,756,200.00. Following the transaction, the director now directly owns 2,269,015 shares in the company, valued at $265,656,276.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, President Stephen Hoge sold 341 shares of the stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $144.50, for a total transaction of $49,274.50. Following the completion of the sale, the president now directly owns 1,471,777 shares of the company’s stock, valued at $212,671,776.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $117.08, for a total value of $1,756,200.00. Following the sale, the director now directly owns 2,269,015 shares of the company’s stock, valued at $265,656,276.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 366,238 shares of company stock worth $51,819,454. Insiders own 15.70% of the company’s stock.
Analyst Ratings Changes
MRNA has been the topic of several research reports. William Blair reissued a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. Piper Sandler reissued an “overweight” rating and set a $157.00 price target (down previously from $214.00) on shares of Moderna in a research report on Friday, August 2nd. Royal Bank of Canada cut shares of Moderna from an “outperform” rating to a “sector perform” rating and reduced their target price for the company from $125.00 to $90.00 in a report on Monday, August 5th. Evercore ISI reaffirmed an “in-line” rating and issued a $120.00 target price on shares of Moderna in a report on Thursday, June 27th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $124.07.
Check Out Our Latest Stock Analysis on Moderna
About Moderna
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
See Also
- Five stocks we like better than Moderna
- Best Stocks Under $10.00
- Why Meta Could Be A $600 Stock Within Weeks
- Stock Average Calculator
- Conservative Portfolio: Strategies for Stability
- What Are Dividend Achievers? An Introduction
- Unlocking Growth: Why Arcos Dorados Belongs in Your Portfolio
Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.